Migros Partners with Keurig Dr Pepper to Bring Coffee B Technology to North America
Keurig Dr Pepper is adopting the Swiss-developed Coffee B capsule-free coffee technology for the North American market.
Stocks · News reference
Barclays Maintains Overweight on Keurig Dr Pepper, Raises Price Target to $41
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Keurig Dr Pepper Reports ~99M Of Tariff Refunds Received As Benefit To Gross Profit During Q3
Multiple Analysts Adjust Price Targets for Keurig Dr Pepper
Several financial institutions, including TD Cowen, Wells Fargo, JPMorgan, and UBS, updated their price targets for Keurig Dr Pepper on November 4, 2026.
Keurig Dr Pepper: 3 Key Takeaways for Long-Term Investors
Keurig Dr Pepper reported Q3 2026 earnings with mixed results: energy drink market share surpassed 10% driven by Ghost, Bloom, and C4 brands, but single-serve coffee sales weakened as budget-conscious consumers shifted to cheaper ground and instant coffee. The company is monetizing non-core assets including a Chobani stake to generate $925 million for debt reduction ahead of its planned 2027 split into separate beverage and coffee businesses.
Morgan Stanley Adjusts Keurig Dr Pepper Price Target to $40 From $38
Morgan Stanley has increased its price target for Keurig Dr Pepper to $40, up from $38.
Barclays Adjusts Price Target on Keurig Dr Pepper to $41 From $38
Barclays has raised its price target for Keurig Dr Pepper to $41 from $38.